Phase 3 Chronic Rhinosinusitis Trial, Completed NCT03055507 Sponsor: University of Washington Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 42 people who had undergone nasal surgery — 16 in a control group and 26 in an ibuprofen group. All 42 participants completed the trial with no drop-outs. The trial was measuring post-operative pain levels, nasal bleeding, and the number of opioid (strong painkiller) pills taken each day after surgery. Pain and bleeding were measured using a visual analogue scale — essentially a 10-centimetre line where 0 means none at all and 10 means the worst imaginable. The reported data shows that for post-operative pain, the control group scored between 3.0 and 3.3 out of 10 across the different measurement time points, while the ibuprofen group scored between 1.7 and 2.3 out of 10. For nasal bleeding on the 0–10 scale, the control group recorded scores of 3.2 and 1.2 across time points, compared with 2.3 and 0.5 for the ibuprofen group. On a separate 0–4 bleeding scale, the control group scored 1.5 and 0.7, while the ibuprofen group scored 0.9 and 0.3. For opioid pill use, the reported data shows both groups took an average of 4 pills per day — the same number for each group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 3 Chronic Rhinosinusitis Trial, Completed

NCT03055507
Completed Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with chronic rhinosinusitis (a long-term sinus condition) and are scheduled to have sinus surgery (a procedure to improve airflow through the sinuses)
  • You are over 18 years old
  • You are able to speak and read English

Who may not be able to join:

  • You cannot take anti-inflammatory pain medicines like ibuprofen due to a health reason, such as chronic kidney disease, stomach ulcers, or a sensitivity to aspirin that affects your breathing (confirm with trial site)
  • You have a history of a bleeding disorder
  • You have sinus cancer
  • You have Cystic Fibrosis
  • You are currently taking blood-thinning or anti-clotting medications during or immediately after the surgery
  • You have a history of long-term pain conditions, fibromyalgia, or addiction to opioid (strong painkiller) medications
  • You experience excessive bleeding during the surgery, as judged by your surgeon
  • You are unable to take acetaminophen (paracetamol/Tylenol) for any reason
  • You currently take pain relief medicines every day, including ibuprofen, other anti-inflammatory drugs, acetaminophen, strong prescription painkillers, or any other pain relievers

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 April 2017
Est. completion
31 December 2017

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pain Visual Analogue Scale (VAS); Pain Visual Analogue Scale; Pain Visual Analogue Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov